Cadonilimab Efficacy and Safety Meta-Analysis for Gastric Cancer

A single-arm meta-analysis of four clinical studies involving 182 patients, evaluating the combination of cadonilimab and chemotherapy for gastric or gastroesophageal junction adenocarcinoma. The study, authored by Likun Yang and published on figshare in March 2026, reports pooled estimates for objective response rate, disease control rate, progression-free survival, and adverse events. The analysis is based on a systematic search of databases up to July 20, 2025.

Use Cases

• Benchmarking treatment efficacy based on pooled objective response rate (57%) and disease control rate (97%) estimates.
• Assessing treatment safety profiles based on the reported incidence of grade ≥3 treatment-related adverse events (35%).
• Comparing outcomes across treatment settings using subgroup analysis results for neoadjuvant versus first-line therapy.
• Supporting clinical trial design by synthesizing early-phase evidence on progression-free survival (median 7.98 months).

Strengths

• Includes specific, pooled efficacy metrics with confidence intervals (e.g., ORR 57%, DCR 97%).
• Reports safety data, including the incidence of specific adverse events (e.g., nausea 72%, neutropenia 51%).
• Conducted a systematic search across five major databases (PubMed, Embase, etc.) and ClinicalTrials.gov.
• Has a clear PROSPERO registration identifier (CRD420251089855) for the systematic review.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Based on a limited number of early-phase studies (four studies, 182 patients).

Provenance

Source

Likun Yang via figshare.

Collection Method

Systematic review and single-arm meta-analysis of published clinical studies.

Time Range

Studies published up to July 20, 2025.

Freshness

Last updated 2026-03-17 13:07:23; freshness should be verified.

Geography

null